Johnson & Johnson
JNJToday
-1.13%
5 Days
+2.70%
1 Month
+7.65%
6 Months
+15.73%
Year to Date
+35.15%
1 Year
+57.75%
Recent
Analysis
Alnylam Pharmaceuticals Inc Stock (ALNY) Moved Up by 7.90% on Sep 2: Facts Behind the Movement
• Alnylam shares surged due to positive clinical data and favorable Wall Street analyst commentary. • Amvuttra demonstrated superior efficacy and strong clinical trial results for treating cardiomyopathy. • The company reports $3.71B in annual revenue and neutral technical indicators.
Novo Nordisk A/S Stock (NVO) Moved Up by 3.17% on Sep 2: What Signal Does It Send?
• Novo Nordisk launched its oral weight-loss treatment in Germany and Greater China. • The company continues executing its multi-billion share repurchase program supporting shareholders. • Annual revenue reached $46.70B with net profit totaling $15.48B.
Johnson & Johnson Stock (JNJ) Opened Up by 3.15% on Sep 2: Key Drivers Unveiled
• Johnson & Johnson shares rose due to defensive sector rotation into healthcare equities. • Progress on talc litigation and FDA clearances bolstered investor confidence and growth strategy. • The company posted strong quarterly earnings, raising full-year operational guidance.
Biontech SE Stock (BNTX) Closed Down by 8.37% on Aug 28: What Signal Does It Send?
• BioNTech and Genentech terminated their Phase 2 autogene cevumeran colorectal cancer trial. • The independent Data Safety Monitoring Board concluded the trial lacked clinical efficacy. • BioNTech reports $3.33B in annual revenue and a net profit of $-1.32B.
Moderna Inc Stock (MRNA) Moved Up by 10.02% on Aug 25: Drivers Behind the Movement
• Moderna shares rallied following Wall Street upgrades and positive oncology trial results. • Phase 3 INTerpath-001 trial results showed significant reduction in melanoma recurrence. • Heavy short-covering activity and bullish technical indicators accelerated the stock's upward move.
Mckesson Corp Stock (MCK) Moved Up by 3.13% on Aug 21: A Full Analysis
• McKesson exceeded Wall Street estimates and raised full-year earnings guidance. • Strong cash flow drove share repurchases and a dividend increase. • Analysts issued Buy ratings with an average price target of $979.83.
Johnson & Johnson's Score
Media Coverage
Analyst Rating
Johnson & Johnson Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Johnson & Johnson Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.51% |
| State Street Investment Management (US) | 5.56% |
| BlackRock Institutional Trust Company, N.A. | 5.44% |
| Vanguard Portfolio Management, LLC | 2.64% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 40.66% |
| Investment Advisor/Hedge Fund | 23.83% |
| Research Firm | 3.28% |
| Pension Fund | 2.20% |
Related Instruments
Popular Instruments
